Payment overview · 2025
General Payments
$1,575.90
63 reported records · 22 companies
Healthcare provider profile · identity verified
Justin Lindquist, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ORLANDO, FL · NPI 1457411944
Verified facts
What the public records show
CMS Open Payments records show Justin Lindquist, M.D. received $1,575.90 in general payments during 2025 across 63 reported records.
Eisai Inc. accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Leqembi, Vyvgart.
ARGENX US, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYVGART as an associated drug or biological on 6851 records involving 2825 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vyvgart by this doctor in 2024.
Eisai Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Leqembi as an associated drug or biological on 28719 records involving 10254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Leqembi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eisai Inc. | Unresolved — no canonical attribution shown | $250.44 | 15.9% | 10 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $193.20 | 12.3% | 7 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $166.52 | 10.6% | 8 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $144.18 | 9.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $138.23 | 8.8% | 6 | 2025 |
| Peter Brasseler Holdings, LLC | Unresolved — no canonical attribution shown | $105.53 | 6.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $84.40 | 5.4% | 3 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $61.97 | 3.9% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $56.27 | 3.6% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $52.78 | 3.4% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $52.33 | 3.3% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $52.03 | 3.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.88 | 3.1% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $28.01 | 1.8% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $22.35 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.04 | 1.3% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.83 | 1.2% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.90 | 1.1% | 1 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $17.70 | 1.1% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.43 | 1.0% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $14.24 | 0.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.64 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,558.00 | 62 |
| Education | $17.90 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $250.44 | 10 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $193.20 | 7 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $144.18 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $97.30 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $84.40 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $74.87 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $74.87 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $69.22 | 4 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $63.36 | 3 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $61.97 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $52.78 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $52.33 | 2 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $52.03 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $33.41 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $28.01 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Leqembi leqembi |
2025 | Leqembi | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYVGART vyvgart |
2025 | Vyvgart | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ARGENX US, INC. Exact reporting entity; no affiliate inference |
2025 | VYVGART open payments reported associated product |
CMS Open Payments — General Payments 6851 supporting records · 2825 recipient NPIs · example record 1240416066 |
Vyvgart · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Eisai Inc. Exact reporting entity; no affiliate inference |
2025 | Leqembi open payments reported associated product |
CMS Open Payments — General Payments 28719 supporting records · 10254 recipient NPIs · example record 1244455613 |
Leqembi · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Propranolol Hcl Er | Propranolol Hcl | 77 | 27 |
| Gabapentin | Gabapentin | 61 | 21 |
| Donepezil Hcl | Donepezil Hcl | 56 | 30 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 55 | 22 |
| Levetiracetam Er | Levetiracetam | 55 | 23 |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 55 | suppressed |
| Amantadine | Amantadine Hcl | 53 | 25 |
| Rizatriptan | Rizatriptan Benzoate | 35 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | 16 |
| Rivastigmine | Rivastigmine Tartrate | 34 | suppressed |
| Lacosamide | Lacosamide | 32 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 14 |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 26 | suppressed |
| Primidone | Primidone | 26 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 19 | suppressed |
| Alprazolam | Alprazolam | 17 | 15 |
| Clonazepam | Clonazepam | 17 | suppressed |
| Vyvgart | Efgartigimod Alfa-Fcab | 17 | suppressed |
| Leqembi | Lecanemab-Irmb | 16 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Protriptyline Hcl | Protriptyline Hcl | 11 | suppressed |
| Sumatriptan | Sumatriptan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,575.90 · 63 records | Eisai Inc. | ACTHAR, AJOVY, BOTOX, DOVATO, Fetroja, HYQVIA, Leqembi, MOUNJARO, NURTEC ODT, PANZYGA, PRECIVITYAD2, Qelbree, Radicava, Rystiggo, TRUDHESA, ULTOMIRIS, UPLIZNA, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, ZAVZPRET, ZEPBOUND, ZERBAXA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Leqembi play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ARGENX US, INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error